Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

Deals > All

Total search results: 10490 | Ordered by Date (descending)
1 2 3 ... 103 104 105  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures 2020-09-17
Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare 2020-09-17
Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC 2020-09-17
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments 2020-09-17
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant 2020-09-17
Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital 2020-09-17
Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech 2020-09-17
Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications 2020-09-16
Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact 2020-09-16
Evotec–BIOASTER: antiinfectives, 202009– collab research to establish tech + innovation hub in Lyon work started in early 2020 2020-09-14
Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital 2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital 2020-09-14
Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners 2020-09-14
Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax 2020-09-14
Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona 2020-09-14
Neogene Therapeutics–Syncona: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Syncona 2020-09-14
Neogene Therapeutics–Texas Pacific Group: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG 2020-09-14
Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River 2020-09-14
Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures 2020-09-14
Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp 2020-09-11
MiNA Therapeutics–SEVERAL: investment, 202009 financing round Series A £23m ($30m) led by new investor aMoon + incl existing investors 2020-09-10
Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation 2020-09-09
Algenex–SEVERAL: investment, 202009 private financing round €7.4m led by MasterLux + incl new investor Columbuus Life Science Fund II 2020-09-08
United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID 2020-09-08
Amarna Therapeutics–LifeSpring: public relations, 202009 service existent by LifeSpring Communications 2020-09-03
Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC 2020-09-03
Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform 2020-09-02
Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery 2020-09-02
AstraZeneca–Oxford BioMedica: contract manufacturing, 202009– supply production capacity for adenoviral vector-based Covid-19 vaccine AZD1222 2020-09-01
Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform 2020-09-01
BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m 2020-09-01
Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 2020-09-01
Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b 2020-08-31
Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures 2020-08-31
Aignostics–Berlin (govt): investment, 202008 seed financing round totalling €5m incl co-investor VC Fonds Technologie der IBB 2020-08-28
Aignostics–Boehringer: investment, 202008 seed financing round totalling €5m incl lead investor BIVF 2020-08-28
Aignostics–Hessen (govt): investment, 202008 seed financing round totalling €5m incl co-investor Future Capital 2020-08-28
Aignostics–High-Tech Gründerfonds: investment, 202008 seed financing round totalling €5m incl co-investor HTGF 2020-08-28
Aignostics–SEVERAL: investment, 202008 seed financing round €5m led by BIVF + incl HTGF + IBB VC Fonds Technologie + Future Capital 2020-08-28
Axol Bioscience–Zyme Communications: public relations, 202008 service existent by Zyme 2020-08-27
Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction 2020-08-27
Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer 2020-08-27
Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures 2020-08-27
Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors 2020-08-26
NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders 2020-08-25
NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall 2020-08-25
NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders 2020-08-25
Takeda–Engitix: antifibrotics, 202008– collab + license agreem up to $500m+ developm for advanced liver diseases incl NASH 2020-08-25
Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system 2020-08-24
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates 2020-08-18
Bayer–Hua Medicine: dorzagliatin, 202008– commercialisation agreement + strategic partnership in China 2020-08-17
Mobilion–SEVERAL: investment, 202008 financing round Series B $35m led by aMoon + incl Agilent + IP Group + Hostplus + Cultivation Capital 2020-08-17
Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share 2020-08-17
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
F2G Ltd–Advent Venture Partners: investment, 202008 financing round totalling $60.8m incl exisiting investor Advent Life Sciences 2020-08-12
F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments 2020-08-12
F2G Ltd–EMS (BR): investment, 202008 financing round totalling $60.8m incl exisiting investor Brace Pharma Capital 2020-08-12
F2G Ltd–Morningside: investment, 202008 financing round totalling $60.8m incl exisiting investor Morningside Ventures 2020-08-12
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos 2020-08-12
Atriva Therapeutics–High-Tech Gründerfonds: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor HTGF 2020-08-11
Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV 2020-08-11
Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF 2020-08-11
Bayer–Atomwise: AI-based drug discovery, 202008 collab existent 2020-08-11
Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
Kandy Therapeutics–Bayer: investment, 202008– acquisition $425m upfront + $450m developm milestones + triple digit $m sales milestones 2020-08-11
Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer 2020-08-11
Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer 2020-08-11
CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market 2020-08-10
Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital 2020-08-10
Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share 2020-08-10
Oasmia–Consilium: public relations, 202008 service existent by CSC 2020-08-10
T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners 2020-08-06
T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF 2020-08-06
T-Knife–RA Capital Management: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor RA Capital 2020-08-06
T-Knife–SEVERAL: investment, 202008 financing round Series A €66m co-led by Versant Ventures + RA Capital 2020-08-06
T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures 2020-08-06
GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund 2020-08-05
GentiBio–OrbiMed: investment, 202008 seed financing round totalling $20m inbcl co-lead investor OrbiMed 2020-08-05
GentiBio–RA Capital Management: investment, 202008 seed financing round totalling $20m inbcl co-lead investor RA Capital Management LP 2020-08-05
GentiBio–SEVERAL: investment, 202008 seed financing round $20m led by OrbiMed + Novartis Venture + RA Capital Management 2020-08-05
Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures 2020-08-05
NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum 2020-08-03
Varian Medical Systems–Siemens: investment, 202008– acquisition $16.4b in cash of Varian Medical Systems Inc by Siemens Healthineers AG ANNOUNCED 2020-08-02
Genespire–Consilium: public relations, 202007 service existent by CSC 2020-07-30
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications 2020-07-29
Abzena–Biospring Partners: investment, 202007 investment $10m by Lifespring Partners 2020-07-28
Enthera–AbbVie: investment, 202007 financing round Series A totalling €28m incl new + co-lead investor AbbVie Ventures 2020-07-28
Enthera–Banca Profilo: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Arepo Fiduciaria 2020-07-28
Enthera–Banor SIM: investment, 202007 financing round Series A totalling €28m incl new + co-investor group co-ordinated by Banor SIM 2020-07-28
Enthera–Indaco Venture Partners: investment, 202007 financing round Series A totalling €28m incl new + co-investor Indaco Venture Partners SGR 2020-07-28
Enthera–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-28
Enthera–Juvenile Diabetes Research Foundation: investment, 202007 financing round Series A totalling €28m incl existing + co-investor JDRF T1D Fund 2020-07-28
1 2 3 ... 103 104 105  next pagenext page



Advertisement

Picture [iito] No Tracking 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top